DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Metrics to compare | DBV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDBVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | 4.0x | −0.5x | |
PEG Ratio | −0.85 | 0.18 | 0.00 | |
Price/Book | 7.6x | 3.2x | 2.6x | |
Price / LTM Sales | 228.4x | 3.8x | 3.2x | |
Upside (Analyst Target) | 38.5% | 59.1% | 48.8% | |
Fair Value Upside | Unlock | 13.1% | 7.6% | Unlock |